Myomo Stock Suffers from Financial Challenges Amid Director's Investment

Myomo Director Thomas Kirk has invested $55,000 in the company's stock by purchasing 50,000 shares. Recent financial disclosures have led to multiple price target adjustments from analysts, with some lowering their targets due to concerns over the drop in patients added to its pipeline and revised revenue forecasts. Myomo's overall stock score is Neutral, primarily impacted by its financial performance challenges and bearish momentum.